The company’s shift toward a multi-condition business model is gaining traction, with over 80% of its $13.1 million in contracted annual recurring revenue now tied to platforms managing multiple chronic conditions. Gross margins saw a meaningful lift to 62%, up from 57% in the first quarter, bolstered by the company’s internal AI-driven optimizations and a favorable product mix.
Commercial momentum appears to be building through enterprise partnerships. Recent wins include an expansion with a top-five national health plan—the company's third such deal—and the addition of its fifth Fortune 50 client. DarioHealth is also venturing deeper into provider-backed care, launching an integrated program for GLP-1 oversight. Following the close of the quarter, the firm bolstered its liquidity, raising $22.8 million in net proceeds through a registered direct financing. CEO Erez Raphael maintains that the current infrastructure investments position the company to accelerate revenue growth through the end of 2026 and into 2027.
Comments (0)
No comments yet. Be the first!